Andrea Bezjak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Bezjak has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Sun
Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
1 shared publication - Andrew Hope
Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Canada
1 shared publication - Anthony M. Brade
Trillium Health Partners, Mississauga, ON L5B 1B8, Canada
1 shared publication - B.C. John Cho
Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada
1 shared publication - Barbara Melosky
BC Cancer, Vancouver Center, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada
1 shared publication - Benjamin H. Lok
Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada.
1 shared publication
Latest Publications
- Open Access
- 17 September 2025
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 36, 100345
A prospective audit of thoracic reirradiation practice and peer-review in a high-volume academic center
- 17 September 2025
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 36, 100345
Open AccessA prospective audit of thoracic reirradiation practice and peer-review in a high-volume academic center
- 13 August 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (1) , 13-14
“We Need to Talk”
- 13 August 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (1) , 13-14
“We Need to Talk”
- Open Access
- 23 October 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6512-6535
Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process
The addition of durvalumab consolidation to concurrent chemoradiation therapy (cCRT) has fundamentally changed the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC). Nevertheless, concerns related to esophagitis and pneumonitis potentially impact the broad application of all regimen components. A Canadian expert working group (EWG) was convened to provide guidance to healthcare professionals (HCPs) managing these adverse events (AEs) and to help optimize the patient experience. Integrating literature review findings and real-world clinical experience, the EWG used a modified Delphi process to develop 12 clinical questions, 30 recommendations, and a risk-stratification guide. The recommendations address risk factors associated with developing esophagitis and pneumonitis, approaches to risk mitigation and optimal management, and considerations related to initiation and re-initiation of durvalumab consolidation therapy. For both AEs, the EWG emphasized the importance of upfront risk assessment to inform the treatment approach, integration of preventative measures, and prompt initiation of suitable therapy in alignment with AE grade. The EWG also underscored the need for timely, effective communication between multidisciplinary team members and clarity on responsibilities. These recommendations will help support HCP decision-making related to esophagitis and pneumonitis arising from cCRT ± durvalumab and improve outcomes for patients with unresectable stage III NSCLC.
- 23 October 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6512-6535
Open AccessEsophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process
The addition of durvalumab consolidation to concurrent chemoradiation therapy (cCRT) has fundamentally changed the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC). Nevertheless, concerns related to esophagitis and pneumonitis potentially impact the broad application of all regimen components. A Canadian expert working group (EWG) was convened to provide guidance to healthcare professionals (HCPs) managing these adverse events (AEs) and to help optimize the patient experience. Integrating literature review findings and real-world clinical experience, the EWG used a modified Delphi process to develop 12 clinical questions, 30 recommendations, and a risk-stratification guide. The recommendations address risk factors associated with developing esophagitis and pneumonitis, approaches to risk mitigation and optimal management, and considerations related to initiation and re-initiation of durvalumab consolidation therapy. For both AEs, the EWG emphasized the importance of upfront risk assessment to inform the treatment approach, integration of preventative measures, and prompt initiation of suitable therapy in alignment with AE grade. The EWG also underscored the need for timely, effective communication between multidisciplinary team members and clarity on responsibilities. These recommendations will help support HCP decision-making related to esophagitis and pneumonitis arising from cCRT ± durvalumab and improve outcomes for patients with unresectable stage III NSCLC.